设计和合成针对JNK1的PROTAC,并对活动进行研究
Yue Guo1, Fengling Liu2, Man Chi2
1Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
研究人员开发了针对蛋白质分解的新型嵌合体 (PROTACs),以降解c-Jun N-终端激酶 (JNK1). 分子PA2表现出抗JNK1活性,为肺纤维化提供了潜在的新治疗策略.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 激酶失调与各种疾病有关,包括癌症和纤维性疾病.
- c-Jun N-终端激酶 (JNK) 是治疗肺纤维化的关键标.
- 使用PROTAC的向蛋白质降解比传统的激酶抑制剂具有优势.
研究的目的:
- 开发新的JNK1向的PROTACs来诱导蛋白质体降解.
- 评估开发的PROTACs对JNK1.1的疗效.
- 探索JNK1向的PROTACs在肺纤维化中的治疗潜力.
主要方法:
- 合成了20个针对JNK1的PROTAC分子.
- 酶测试以评估JNK1抑制.
- 蛋白质降解试验证实了JNK1.1的蛋白质体降解.
主要成果:
- 开发了20个针对JNK1的PROTACs.
- 确定PA2是最强大的分子.
- PA2表现出显著的抗JNK1活性,并诱导JNK1降解.
结论:
- 针对JNK1的PROTACs在降解JNK1方面是有效的.
- 作为肺纤维化治疗的治疗剂,PA2显示出前途.
- 在纤维性疾病中,PROTAC技术为准激酶提供了一种可行的策略.
更多相关视频
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Receptor Tyrosine Kinases
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
